Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.

Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P.

Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 2015 Sep 1.

2.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

Hose D, Seckinger A, Jauch A, Rème T, Moreaux J, Bertsch U, Neben K, Klein B, Goldschmidt H.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:84-9.

3.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY.

J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.

4.

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group.

Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. Epub 2012 Oct 3.

5.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C.

Blood. 2007 Apr 15;109(8):3489-95. Epub 2007 Jan 5.

6.

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628. Epub 2011 Oct 10.

7.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):555-562. doi: 10.1016/j.clml.2017.06.020. Epub 2017 Jul 4.

PMID:
28735890
8.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P.

J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.

9.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.

Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10.

10.

Improved risk stratification in myeloma using a microRNA-based classifier.

Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ.

Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394. Epub 2013 May 30.

PMID:
23718138
11.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group.

Leukemia. 2012 Feb;26(2):349-55. doi: 10.1038/leu.2011.204. Epub 2011 Aug 12.

12.

[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21. Chinese.

PMID:
18843972
13.

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A.

J Clin Oncol. 2009 Sep 1;27(25):4197-203. doi: 10.1200/JCO.2008.19.1916. Epub 2009 Jul 27. Erratum in: J Clin Oncol. 2012 Apr 20;30(12):1398.

14.

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.

PMID:
27425179
15.
16.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H.

Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30.

17.

Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.

Sagaster V, Kaufmann H, Odelga V, Ackermann J, Gisslinger H, Rabitsch W, Zojer N, Ludwig H, Nösslinger T, Zielinski C, Drach J.

Eur J Haematol. 2007 Mar;78(3):227-34. Epub 2007 Jan 23.

PMID:
17253972
18.

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.

Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, Dimopoulos MA.

Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27.

19.

Genomic analysis of high-risk smoldering multiple myeloma.

López-Corral L, Mateos MV, Corchete LA, Sarasquete ME, de la Rubia J, de Arriba F, Lahuerta JJ, García-Sanz R, San Miguel JF, Gutiérrez NC.

Haematologica. 2012 Sep;97(9):1439-43. doi: 10.3324/haematol.2011.060780. Epub 2012 Feb 13.

20.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13. Erratum in: Cancer. 2011 Jul 1;117(13):3060.

Supplemental Content

Support Center